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Abstract
OBJECTIVE: The objective of this systematic review is to determine whether or not
levofloxacin is a more effective treatment than ciprofloxacin in adult patients with Acute
Pyelonephritis (AP).
STUDY DESIGN: Review of three English language primary double-blind randomized
controlled trial studies comparing levofloxacin to ciprofloxacin for the treatment of AP in adults.
DATA SOURCES: Randomized controlled double-blind comparative trials were found using
Cochrane, PubMed, and Science Direct databases.
OUTCOME MEASURED: All studies measured three outcomes: microbiologic eradication,
clinical response, and safety and tolerability of the medication. Microbiologic eradication was
measured by urine culture which demonstrated a reduction of pathogens to <104 CFU/mL.
Clinical response was measured by: cured (complete resolution of signs and symptoms
associated with active infection); improved (incomplete resolution of signs and symptoms but no
additional antimicrobial therapy required); failed (no response to therapy); or unable to evaluate
(patient did not return for follow-up evaluation). Safety and tolerability information was
collected through post therapy follow up visits.
RESULTS: The dichotomous data systematically reviewed in all three RCTs determined that
there is a minimal relative and absolute benefit increase in the use of levofloxacin over
ciprofloxacin in the treatment of AP in adults. Confidence Intervals calculated in all studies
prove that this data is statistically significant. Adverse events and/or serious adverse events were
noted in all three trials with the use of both levofloxacin and ciprofloxacin, however, very few
were considered to be treatment related.
CONCLUSIONS: The results of these three studies show that the use of levofloxacin for the
treatment of AP in adult patients is as effective as ciprofloxacin in regard to microbiologic
eradication, efficacy, and safety and tolerability.
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Introduction
Urinary tract infection (UTI) is a broad term encompassing any infection along the urinary
tract or in urinary organs such as the kidney or bladder. Microorganisms detected in the urine at
>105 colony forming units (CFU) per milliliter from a midstream clean catch urine specimen is a
significant laboratory finding in the diagnosis of a UTI1. Additionally, more than 5 white blood
cells per high power field1, hematuria, and cloudy or malodorous urine may be present in the
specimen.
Acute Pyelonephritis (AP) is classified as a UTI, specifically of the renal parenchyma.
Patients may present with varying symptoms, however, urinary frequency, urgency, and dysuria,
along with costovertebral angle (CVA) tenderness radiating to the groin are most commonly
seen2. Systemic symptoms such as fever, tachycardia, nausea, vomiting, or diarrhea will also be
present. AP is a treatable condition but can become very dangerous if not tended to quickly or
properly. Infection can spread from the kidney to the peritoneum which can become life
threatening3. This paper evaluates three double blind randomized controlled trials comparing
levofloxacin use to ciprofloxacin use for the effectiveness in the treatment of AP in adults.
Microbiologic eradication, clinical response, and safety and tolerability of the medications are
assessed.
AP is most commonly seen in women and affects an estimated 250,000 Americans each
year1. Results from a 1995-96 survey showed that there are about 4,922,000 visits for
unspecified UTIs each year, and of the visits that prove to be AP, 10-30% require
hospitalization2. Cost has proven to be incredibly high, not just in the treatment of AP, but also in
work loss and non-medical expenses. A study conducted by Brown et al in 2005 demonstrates
what has been spent annually: $351 million as a result of work loss due to death, $398 million as
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a result of work loss due to disability, $92.5 million due to non-medical expenses, and $1.3
billion due to medical expenses. This adds up to $2.14 billion being spent annually for the
treatment and associated issues caused by AP 2.
Gram negative bacteria, specifically Escherichia coli, are the most common causative agent
of AP. Proteus mirabilis, Klebsiella pneumoniae, and Enterobacter cloacae are other common
uropathogens1. Antimicrobial therapy, therefore, is aimed at targeting these gram negative
bacteria. Fluorquinolone therapy for 7-14 days is currently the treatment of choice for AP5.
Patients should be hospitalized and given intravenous fluoroquinolone therapy if they have
severe infection or co-morbidities. Uncomplicated AP is treated with outpatient oral antibiotics
such as 500 milligrams of Ciprofloxacin twice a day for 10 days or 250 milligrams of
Levofloxacin once a day for 10 days. Both of these fluorquinolones are considered to be
effective treatments for AP3. Levofloxacin, however, may provide a higher cure rate, quicker
reduction in signs and symptoms, and less adverse drug reactions as compared to Ciprofloxacin
in the treatment of AP in adult patients.

Objective
The objective of this systematic review is to determine whether or not levofloxacin is a more
effective treatment than ciprofloxacin in adult patients with AP.

Methods
Three randomized controlled trials (RTCs) were selected through a detailed search of articles
via the Cochrane, PubMed, and Science Direct databases. Key words searched included “acute
pyelonepthritis”, “urinary tract infection”, “levofloxacin”, and “ciprofloxacin”. These words in
combination provided three double-blind RCTs comparing levofloxacin to ciprofloxacin in the
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Table 1: Demographics of included studies
Study
Type
#
Age Inclusion Criteria
pts
Richard1, Double 186 18Male or female
1998
blind,
91
≥18 with > 5
RCT
WBC per high
power field (hpf)
or > 20 WBC per
low power field
and > 105 CFU/
mL in urine; two
of the following:
flank pain or
CVA tenderness,
fever, peripheral
WBC count
>15,000/ mm3,
WBC casts in
urine
Klausner3 Double 311 ≥18 Male or female
, 2007
blind,
≥18; + dipstick
RCT
for leukocytes; ≥
5 WBC per hpf in
urine; 2 of the
following: fever,
flank pain or
CVA tenderness,
peripheral WBC
> 12,500/mm3 or
≥ 10% bands,
WBC casts in the
urine; 1 of the
following:
nausea, vomit,
dysuria, urgency,
frequency
4
Peterson , Double 506 ≥18 Male or female
2008
blind,
≥18; > 105 CFU
RCT
in urine; 2 of the
following: fever;
flank pain or
CVA tenderness;
peripheral WBC
> 12,500/mm5 or
10% bands; WBC
casts in the urine

Exclusion Criteria W/
D
Treated with
0
antibiotic in the
past 24 hrs;
requiring IV
antibiotics;
history of allergic
reaction to
quinolone;
obstruction,
prostatitis,
resistant pathogen
pregnancy,
seizure d/o; renal
clearance < 50 ml
/min; weight < 40
kg
Cystitis, chronic
8
pyelonephritis,
obstruction,
prostatitis, PKD,
renal transplant,
HIV, pregnancy;
received > 1 dose
antibiotic for
presenting UTI
w/i 5 days of
study entry;
resistant pathogen
Renal clearance <
50 ml/min

Obstruction, need
for lithotripsy,
additional
antimicrobial
therapy; resistant
pathogen; renal
abscess;
prostatitis;
epididymitis

0

Intervention
Levofloxacin
250 mg QD
for 10 days

Levofloxacin
750 mg QD
for 5 days

Levofloxacin
750 mg QD
for 5 days
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treatment of adults with AP and addressed patient-oriented evidence that matters (POEMs).
Studies were excluded if subjects were suffering from unspecified urinary tract infections or if
subjects were under the age of 18. Outcomes measured were microbiologic eradication, clinical
response, and safety and tolerability of the medication.
Variation between studies was minimal. In both the Klausner 2007 study and the Peterson
2008 study, 750 mg of levofloxacin once daily for 5 days was compared to the control group of
500 mg of ciprofloxacin twice daily for 10 days. In the Richard, 1998 study, 250 mg of
levofloxacin once daily for 10 days was compared to the control group of ciprofloxacin 500 mg
twice daily for 10 days. Lastly, the Peteron 2008 study includes treatment of complicated urinary
tract infections in addition to AP.
All articles were published in English in peer reviewed journals from 1998-2007. Statistics
used in the studies included RBI, ABI, NNT, NNH, and CI. Table 1 provides demographic
information of all articles included.

Outcomes Measured
Outcomes of all three studies were measured by microbiologic eradication, clinical response,
and safety and tolerability of the medication. Microbiologic eradication was defined as a urine
culture demonstrating an absence or reduction of uropathogens to <104 CFU/mL1,4,5.
Clinical response was measured by signs and symptoms experienced by the subject.
“Clinically cured” was defined as the complete absence of signs and symptoms associated with
active infection including flank pain, fever, and painful urination. “Clinically improved” was
incomplete resolution of signs and symptoms, however, subjects would not require further
antimicrobial therapy. “Clinically failed” was defined as no response to the antimicrobial
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therapy. Lastly, “unable to evaluate” was assigned to subjects who did not return for follow-up
evaluation1,4,5.
Safety and tolerability information was collected through post therapy follow up visits.
Information on adverse events was collected throughout the study up to 30 days after the last
dose of medication was administered. Serious adverse events were reported by subjects or
witnessed in the laboratory.

Results
This systematic review includes three double-blind, randomized controlled trials, all of
which were comparative ten day trials. The control group in all three studies was ciprofloxacin
500 mg taken twice a day for ten days, while the experimental group was levofloxacin 750 mg
once daily for five days in two of the studies (Klausner 2007 and Peterson 2008), and
levofloxacin 250 mg once daily for ten days in the third study (Richard 1998). The Klausner
2007 and Peterson 2008 studies performed blinded therapy for ten days with both drugs so as not
to alter any results. Patients being treated with levofloxacin were given a placebo in the evening
days one through five and a placebo twice daily days six through ten. Each study was performed
in adult patients microbiologically and clinically diagnosed with AP. Patients were excluded if
they had taken any antimicrobial therapy for their current condition. Treatment prior to
administration of trial therapy would skew the results because patients would already be on the
way to being cured. In all three studies, Escherichia coli were found to be the most commonly
isolated uropathogen.
All three studies presented with “dichotomous” data, so no data had to be converted. The
Relative Benefit Increase (RBI), Absolute Benefit Increase (ABI), and Numbers Needed to Treat
(NNT) were calculated using efficacy rates for both the levofloxacin and ciprofloxacin treated
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patients. These values were calculated using clinical success rates with levofloxacin as the
Experimental Event Rate (EER) and clinical success rates with ciprofloxacin as the Controlled
Event Rate (CER). A summary of these analyses along with the Confidence Interval (CI) from
each study can be found in Table 2. The CI determines whether the data is valid by showing how
precise the estimate of the cliabnical success rates (treatment effect) is. A CI that contains the
relative risk of 1.00 proves that there is no significant difference between treatment effects.
Table 2: Analysis of Levofloxacin versus Ciprofloxacin on clinical success at post-therapy visit
Levofloxacin Ciprofloxacin
CI (%)
RBI
ABI
NNT
EER (%)
CER (%)
Klausner
86.2
80.6
-15.1 to 6.1
6.9
5.6
18
2007
Peterson
79.8
77.5
-9.6 to 1.2
2.9
2.3
44
2008
Richard
92
88
-16.4 to 4.0
4.5
4
25
1998
The Klausner 2007 study evaluated 80 levofloxacin-treated patients and 76 ciprofloxacintreated patients. Results showed an 86.2% success rate with levofloxacin as compared to an
80.6% success rate with ciprofloxacin. The RBI and ABI are not high percentages but do show
some benefit to using levofloxacin. Additionally, the NNT shows that for every 18 patients
treated with levofloxacin, one more will have microbiologic eradication versus ciprofloxacin. A
CI of -15.1 to 6.1, however, shows no statistical difference between clinical success rates of
levofloxacin to ciprofloxacin.
265 participants were treated with levofloxacin while 241 participants were treated with
ciprofloxacin in the Peterson 2008 study. Success rates for the experimental group were
calculated to be 79.8% with the control group close behind at 77.5%. This study also shows a
small RBI and ABI; however, they still indicate benefit to using levofloxacin. The NNT was
higher compared to other studies, but showed that for every 44 participants treated with
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levofloxacin, 1 more will have microbiologic eradication than with ciprofloxacin. The CI
calculated for this study includes a relative risk of 1.00, meaning there is no statistical difference
between the treatment effect of levofloxacin as compared to ciprofloxacin.
Lastly, the Richard 1998 trial showed similar results when compared to both other
studies. The trial assessed 89 levofloxacin-treated patients and 58 ciprofloxacin-treated patients.
An RBI of 4.5% and ABI of 4% show there is minimal benefit to the use of ciprofloxacin, and
the NNT shows that for every 25 participants treated with levofloxacin, 1 more will have
microbiologic eradication than with ciprofloxacin. Again, data recovered from this study does
not prove a significant difference between treatment effect as shown by the calculated CI.
As previously discussed, safety and tolerability of both levofloxacin and ciprofloxacin
were evaluated in all three studies. The analysis of outcomes and Numbers Needed to Harm
(NNH) for each trial is provided in Table 3. A patient who experienced any adverse event or side
effect thought to be related to treatment was included. The NNH was calculated by dividing 1
over the Absoulte Risk Increase (ARI), the value of which was rounded to a whole number.
Table 3: Analysis of Levofloxacin versus Ciprofloxacin on safety and tolerability at posttherapy visit
Levofloxacin Ciprofloxacin
RRI
ARI
NNH
EER (%)
CER (%)
Klausner
43.8
39.2
11.7
4.6
22
2007
Peterson
35.5
33.1
7.2
2.4
42
2008
Richard
2
8
-75
-6
17
1998
There were many adverse effects (AE) of reported throughout all three studies which
comprises the safety and tolerability of both antimicrobial treatments. In the Klausner 2007
study, the most common side effects recorded were headache and nausea. 2.7% of levofloxacintreated patients and 1.2% ciprofloxacin-treated patients experienced either one or both of these
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symptoms. Serious adverse effects (SAEs) were seen in 5 of 146 patients treated with
levofloxacin and 6 of 166 patients treated with ciprofloxacin, however, these SAEs were
determined to be “unrelated to study medication”4.
The Peterson 2008 trial most commonly reported nausea, headache, and diarrhea as
adverse events, however, saw no noteworthy difference in the number of patients complaining of
these symptoms between the two treatments. An allergic reaction to levofloxacin seen in one
patient was the only AE determined to be related to treatment. Two deaths occurred in this study,
however, neither was considered to be related to treatment.
A larger number of patients were considered evaluable for safety than were considered
evaluable for microbiologic eradication in the Richard 1998 study. 3 of 124 levofloxacin-treated
patients and 6 of 80 ciprofloxacin-treated patients experienced an AE, all of which are
“gastrointestinal” in nature such as diarrhea, nausea, and flatulence. Vaginitis was also reported,
however, there were no SAEs noted in this trial.

Discussion
Levofloxacin was approved by the FDA in 1996 for AP. Additionally, it was approved
for chronic bronchitis, pneumonia, chronic bacterial prostatitis, sinusitis, skin infections, and
inhalational anthrax2. There are, however, contraindications to the use of levofloxacin in the
treatment of any of these conditions. For example, people with myasthenia gravis may
experience exacerbations of muscle weakness so levofloxacin should not be prescribed for these
patients. Hypokalemia and a prolonged QT interval are other noted contraindications. Lastly, a
black box warning for all fluoroquinolones states there is an increased risk of tendon rupture
with their use2. There are a number of non life-threatening AEs caused by levofloxacin, some of
which were experienced by patients in the RCT’s utilized for this systematic review. The
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Klausner 2007 study showed five prominent AEs including “unintended pregnancy, urinary
calculus, non-cardiac chest pain, pelvic inflammatory disease, and urinary retention”. Flatulence,
vaginitis, and diarrhea were the most common AEs in the Richard 1998 study. Lastly, the
Peterson 2008 study noted that headache, nausea, and diarrhea were the most frequent AEs.
There were limitations to each article. Both the Peterson 2008 and the Klausner 2007
articles analyzed results from larger trials which included patients with chronic UTIs in addition
to AP. Additionally, they both compared a trial of Levofloxacin for 5 days to Ciprofloxacin for
10 days. The shortened duration of Levofloxacin therapy may skew end of therapy and post
therapy values in favor of Ciprofloxacin, the antimicrobial agent which was used for a longer
period of time. The Richard 1998 study specified that patients were required to have 105
CFU/mL of a uropathogen for inclusion, which they deemed may be too high of a threshold for
treatment. However, all studies required a 105 CFU/mL threshold for inclusion so this is not a
limitation in regard to this systematic review.

Conclusion
All three studies systematically reviewed concluded that levofloxacin is as effective as
ciprofloxacin in treating adult patients with AP; however, it was not proven to be a more
effective treatment in terms of microbiologic eradication, clinical success, and safety and
tolerability.
Future studies should address the effectiveness of levofloxacin as compared to
ciprofloxacin as far as compliance. Because levofloxacin is only taken once a day for five days,
it is much more likely that patients comply with the prescribed treatment. Comparatively
speaking, ciprofloxacin must be taken twice a day for ten days, making it less likely for patients
to remember to take the medication or to finish the full length of treatment.
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Further research can also be performed in determining uropathogen susceptibility
differences between levofloxacin and ciprofloxacin. Resistance is a major issue being faced by
all parts of the world, and extra research in this area would be helpful in determining how well
levofloxacin and ciprofloxacin function in eradication of resistant pathogens. The studies
systematically reviewed here touched upon these differences, however, did not go into any
length or detail in showing whether one fluoroquinolone was superior to the other in these terms.
In conclusion, this systematic review proves that when compared with ciprofloxacin,
levofloxacin is also a safe and effective empiric antimicrobial choice for therapy in the treatment
of AP in adult patients. However, further studies showing resistance patterns and patient
compliance could show that levofloxacin is the better choice.
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